EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety of COVID-19 vaccines in pregnancy: a VAERS based analysis

Greta Santi Laurini, Nicola Montanaro, Domenico Motola

European Journal of Clinical Pharmacology · 2023

DOI: 10.1007/s00228-023-03482-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Pharmacology, 2023. Verfasst von Greta Santi Laurini und 2 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Pharmacology, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Vaccines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alma Mater Studiorum - Università di Bologna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Since vaccination against COVID-19 is recommended in pregnant people, we aimed to provide further evidence on the safety profile of COVID-19 vaccines in pregnancy.

Methods

Data on COVID-19 vaccines adverse events following immunizations (AEFIs) in pregnant people were retrieved from the open-access Vaccine Adverse Event Reporting System (VAERS) from December 2020 to April 2022.

Results

From December 2020 to April 1, 2022, a total of 4,869 reports involving pregnant women at COVID-19 vaccination were reported to VAERS. Among vaccines recipients, most belonged to the age group between 30 and 39 years old (3,029; 62.21%) and nearly half experienced an adverse event within 48 h of immunization (2,344; 48.14%). Overall, 21,816 suspected adverse reactions associated with COVID-19 vaccines were reported, and for as many as 80.43% of patients, they were described as non-serious. Most reactions occurred after administration of the mRNA-1273 (53.34%) and the BNT162b2 (40.68%) vaccines, while only a small proportion were related to the Johnson & Johnson’s vaccine (5.69%). The most common non-pregnancy specific adverse events were headache (482; 2.21%), fatigue (472; 2.16%), and pyrexia (436; 2.00%), while adverse pregnancy outcomes with the highest reporting rate were abortions spontaneous (762; 3.49%), and vaginal haemorrhage (229; 1.05%).

Conclusion

This post-marketing survey on VAERS data have provided updated evidence on the safety of COVID-19 vaccines during pregnancy, thus supporting clinicians in recommending maternal immunization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 VaccinesVaccinesAdultFemaleHumansPregnancyAdverse Drug Reaction Reporting SystemsBNT162 VaccineUnited States

Stichwörter der Autor:innen

Adverse eventsCOVID-19PregnancySafetySurveillanceVaccines

Substanzen

BNT162 VaccineCOVID-19 VaccinesVaccines

Autor:innen und Institutionen

  • Unit of Pharmacology, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
  • Former Professor of Pharmacology at the Alma Mater Studiorum, University of Bologna, Bologna, Italy.
  • Unit of Pharmacology, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy. domenico.motola@unibo.it.

Förderung

  • Alma Mater Studiorum - Università di Bologna

Zitieren

APA

Santi Laurini, G., Montanaro, N., & Motola, D. (2023). Safety of COVID-19 vaccines in pregnancy: a VAERS based analysis. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-023-03482-8

Vancouver

Santi Laurini G, Montanaro N, Motola D. Safety of COVID-19 vaccines in pregnancy: a VAERS based analysis. European Journal of Clinical Pharmacology. 2023. doi:10.1007/s00228-023-03482-8

BibTeX
@article{SantiLaurini2023,
  author = {Santi Laurini, Greta and Montanaro, Nicola and Motola, Domenico},
  title = {Safety of COVID-19 vaccines in pregnancy: a VAERS based analysis},
  journal = {European Journal of Clinical Pharmacology},
  year = {2023},
  doi = {10.1007/s00228-023-03482-8}
}
Kostenlos starten →